Nirmatrelvir-ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022-23: virological and immunological results of an open-label randomised trial (PANORAMIC).

Saved in:
Bibliographic Details
Title: Nirmatrelvir-ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022-23: virological and immunological results of an open-label randomised trial (PANORAMIC).
Authors: Lowe DM; Institute of Immunity and Transplantation, University College London, London, UK; Department of Clinical Immunology, Royal Free London NHS Foundation Trust, London, UK. Electronic address: d.lowe@ucl.ac.uk., Zhang S; Infection, Immunity, and Inflammation, Great Ormond Street Institute of Child Health, University College London, London, UK., Ellis S; Infection, Immunity, and Inflammation, Great Ormond Street Institute of Child Health, University College London, London, UK., Buggiotti L; Infection, Immunity, and Inflammation, Great Ormond Street Institute of Child Health, University College London, London, UK., Miller C; Great Ormond Street Hospital for Children NHS Trust, London, UK., Harris V; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Shields AM; Clinical Immunology Services, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK., Richter AG; Clinical Immunology Services, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK., Ashmore E; Clinical Immunology Services, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK., Yu LM; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Khoo S; Department of Pharmacology, University of Liverpool, Liverpool, UK; Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK., Hobbs FDR; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Little P; Primary Care Research Centre, University of Southampton, Southampton, UK., Butler CC; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Breuer J; Infection, Immunity, and Inflammation, Great Ormond Street Institute of Child Health, University College London, London, UK; Great Ormond Street Hospital for Children NHS Trust, London, UK., Standing JF; Infection, Immunity, and Inflammation, Great Ormond Street Institute of Child Health, University College London, London, UK; School of Pharmacy, University College London, London, UK; Great Ormond Street Hospital for Children NHS Trust, London, UK.
Corporate Authors: PANORAMIC Trial Collaborative Group and PANORAMIC Trial Virology Group
Source: The Lancet. Microbe [Lancet Microbe] 2026 May; Vol. 7 (5), pp. 101360. Date of Electronic Publication: 2026 Apr 23.
Publication Type: Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101769019 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-5247 (Electronic) Linking ISSN: 26665247 NLM ISO Abbreviation: Lancet Microbe Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-5247
DOI:10.1016/j.lanmic.2026.101360